IMP3, a Promising Prognostic Marker in Clear Cell Renal Cell Carcinoma
Korean Journal of Pathology
; : 108-116, 2014.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-20021
Responsible library:
WPRO
ABSTRACT
BACKGROUND:
Insulin-like growth factor II mRNA-binding protein 3 (IMP3) has been reported as a prognostic biomarker in various cancers. To validate IMP3 as a prognostic biomarker in renal cell carcinoma (RCC), we investigated the expression of IMP3, p53, and Ki-67, and their associations with clinicopathologic outcomes.METHODS:
We studied 148 clear cell RCCs (CCRCCs) from patients who underwent radical nephrectomy. The expression levels of IMP3, p53, and Ki-67 were assessed by immunohistochemical staining and the clinical and pathologic parameters were retrospectively reviewed.RESULTS:
Twenty-nine percent of CCRCCs expressed IMP3. Forty-one percent of IMP3-immunopositive tumors developed metastases, while only 11.4% of IMP3-negative tumors developed metastases (p<.001). A Kaplan-Meier curve showed that patients with IMP3-immunopositive tumors had lower metastasis-free survival and cancer-specific survival than did those with IMP3-immunonegative tumors (p<.001 and p<.001, respectively). Expression of high Ki-67 proliferation index was also associated with a higher metastatic rate. In the multivariate Cox regression analysis, pT stage and IMP3-positivity were independently associated with disease-specific survival.CONCLUSIONS:
IMP3 is an independent prognostic biomarker for patients with CCRCC to predict metastasis and poor outcome.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Insulin-Like Growth Factor II
/
Carcinoma, Renal Cell
/
Retrospective Studies
/
Tumor Suppressor Protein p53
/
Neoplasm Metastasis
/
Nephrectomy
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Korean Journal of Pathology
Year:
2014
Document type:
Article